Archives

Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher

B First Targeted Therapy Approved for NRG1+ Cholangiocarcinoma BIZENGRI Now Approved for Patients Harboring NRG1 Gene Fusions in Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, and… Login to continue reading Login…

Read MorePartner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher

Binance Expands Institutional Loan Access to All KYB-Verified VIP Clients, Adds Interest Rebates, Higher Leverage, and Fixed-Rate Options

B ABU DHABI, UAE, May 11, 2026 /PRNewswire/ — Binance has expanded access to Binance Institutional Loan, making the product available to all KYB-verified VIP… Login to continue reading Login…

Read MoreBinance Expands Institutional Loan Access to All KYB-Verified VIP Clients, Adds Interest Rebates, Higher Leverage, and Fixed-Rate Options